The genes of seven structural mutants of antithrombin III (ATIII), presenting either defective serine protease reactivity or abnormal heparin binding, were analyzed. The polymerase chain reaction (PCR) was used to amplify the corresponding gene exon and the mutation was identified by either dot blot analysis using a battery of allele-specific oligonucleotide probes or sequencing.
Introduction
Qualitatively deficient antithrombin III (ATIII),' a circulating glycoprotein that plays a major role in the physiological inhibition of blood coagulation, is a classical but rare cause ofthrombosis.
Identification of the mutation responsible for this deficiency is important for at least two major reasons: (a) to demonstrate a correlation between clinical events, generally recurrent thromboembolisms, and a particular molecular defect of antithrombin III; (b) to provide a better understanding of the 1. Abbreviations used in this paper: ASO, allele-specific oligonucleotide; ATIII, antithrombin III; DVT, deep venous thrombosis; WT, wild-type. structural features responsible for the function of the protein's two functional domains: the heparin binding site located near the NH2 terminus (1) , which interacts with heparin to modify the affinity of antithrombin for its protease (2) , and the COOH-terminal reactive site, which forms a covalent complex with thrombin after cleavage of the Arg 393-Ser 394 bond (3) .
Identification of these mutations was, until recently, quite difficult. But the cloning and sequencing of the ATIII cDNA and gene (4) (5) (6) (7) , together with rapid improvements in the techniques of molecular biology (enzymatic amplification ofgenomic DNA plus dot-blot analysis with specific oligonucleotide probes) now allow direct investigation of ATIII gene abnormalities.
This report describes the diagnosis ofthe mutation in seven families presenting with a qualitative antithrombin deficit. Analysis of these patients provides new insights into the structure and the function of ATIII and the resulting data give a clear indication of the thrombotic risk associated with each mutation.
Methods

Patients
Five ATIII variants, referred to as heparin binding-site variants (HBS variants) , were defined by their low antiprotease activity (< 50%) in the presence but not the absence of heparin and normal immunoreactive ATIII. The propositi of ATIII Paris (8) and Paris 2 (9) presented with severe thrombotic complication, but all the other family members having the protein abnormality were asymptomatic. None ofthe three other cases had thrombosis. The Clichy abnormality was detected in a 24-yr-old woman presenting with a thoracic outlet syndrome (10) . The Franconville variant was diagnosed in a 25-yr-old woman who presented with a retroplacental hemorrhage, which led to fetal death in the 7th mo of pregnancy. No relationship could be established between this clinical event and the defective ATIII. Her mother and two sisters had the same protein abnormality but no thrombotic history; one brother was unaffected. The Clichy 2 variant was discovered fortuitously in a 25-yr-old woman before she started oral contraception. She had no personal or familial history of thrombosis. Three members of the ATIII Alger family (11) were also tested, and used as positive controls. One was homozygous, and the other two were heterozygous, for the Arg 47 Cys mutation. The incidence ofdeep venous thrombosis (DVT) in the heparin binding-site variants of our series, together with those in the literature, is shown in Table I .
Two variants, referred to as reactive-site variants, were also studied.
They are defined by a low (. 50%) antiprotease activity in both the presence and absence ofheparin. The clinical and biological features of these two cases have been described ( 12, 13 Reference numbers are in parentheses.
erly, MA). Klenow fragment of E. coli DNA polymerase I was from Boehringer Mannheim GmBH (Mannheim, FRG). Thermus aquaticus polymerase was from Cambio (Cambridge, UK). Deoxynucleotides. Deoxyadenosine triphosphate (dATP), deoxycytosine triphosphate (dCTP), deoxythymidine triphosphate (dTTP), and deoxyguanosine triphosphate (dGTP) were purchased from Pharmacia Fine Chemicals (Uppsala, Sweden).
Experimental protocols
Oligonucleotides were synthesized on a gene assembler (Pharmacia Fine Chemicals) using the fl-cyanoethyl phosphoramidite method and purified on polyacrylamide gels. The sequences of all the oligonucleotides are summarized in Table II Quality control ofthe amplified material was performed by electrophoresis on 3% agarose gel and Southern blot hybridization (17) with specific ASO probes (PS3 for amplified exon II and PS9 for amplified exon VI). Dot-blot analysis. A 10-Al aliquot of each amplified sample was denatured with 0.4 N sodium hydroxide and 25 mM EDTA in a final volume of 200 M,l heated for 2 min at 950C, and cooled on ice. Duplicate 100-Ml aliquots of each sample were placed in the wells of hybridot manifold (Bethesda Research Laboratories, Bethesda, MD) containing a nylon membrane (Biotrace RP, Gelman Sciences, Inc., Ann Arbor, MI). The samples passed through the filter under vacuum, and the filter was rinsed quickly in 2X SSPE (I X SSPE = 0.18 M NaCl, 10 mM NaH2PO4, I mM EDTA, pH 7.4) and baked for 2 h at +80°C. Prehybridization (30 min) and hybridization with the labeled ASO probe (1 h) were carried out in plastic sealing bags containing 5X SSPE, 5X Denhardt's and 0.5% SDS (solution A), between 42 and 50°C, depending on the melting temperature ofthe DNA duplex (Tm) ofeach ASO probe.
After hybridization, filters were rinsed twice with 6X SSPE, 0.1% SDS (solution 1) at room temperature, washed 10 min in 2X SSPE, 0.1% SDS (solution 2) at a temperature determined by the Tm of the probe, and then exposed to x-ray film for 1-2 h at -80°C with one intensifying screen (Philips Electronic Instruments, Mahwah, NJ).
Subcloning and sequencing. 50 ,ul ofamplified genomic DNA was 5' end-phosphorylated with I Ml 10 mM ATP using T4 polynucleotide kinase in 60 Ml (final volume) for I h at 37°C, purified on a Nen-Sorb 20 column (New England Nuclear Research Products, DuPont Co., Wilmington, DE), lyophilized, and redissolved in 35 ,l distilled water. Blunt-end ligation of 5 Ml of the phosphorylated samples with 50 ng of bacteriophage M 13 mp 18 digested with Sma I was performed for 16 h at 1 4°C. After transformation, recombinant phages were screened with two oligonucleotide probes, which were 5' end-labeled with [32P]dATP.
The probes were PS3 and PSI 6 for the heparin binding site, and PS9 and PS13 for the reactive site (Table II) heterozygous, as previously described (20) . The two other variants (Paris 1 and Paris 2) are also heterozygous for the same mutation. All the samples gave a positive signal at position 41 with the WT probe (Pro). Three variants (Clichy, Clichy 2, and Franconville) also hybridized with the mutated probe (Leu), indicating that they are heterozygous for the mutation (CCG) Pro 41 Leu (CTG). Fig. 2 shows the dot-blot analysis of the amplified reactive site sequence. The three DNAs tested hybridized with the WT probe, but that ofATIII Avranches also hybridized with one of the mutated probes, identifying a point mutation of the cleavage site sequence, His 393-Ser 394 instead of Arg 393-Ser 394. None of the variants reacted with either the mutant leucine 394 probe or the cysteine 393 probe (data not shown).
The second active site variant (ATIII Charleville) thus was the only one for which the mutation could not be identified by dot blot using ASO to previously identified mutants.
Sequencing ofamplified sequences. All the amplified DNAs were subcloned and sequenced to confirm the six mutations Fig. 3 .
Six single-stranded templates corresponding to the amplified DNA of ATIII Charleville were also sequenced. Two of them exhibited the same point mutation in position 384, GCA to CCA, leading to the substitution of alanine 384 for proline (Fig. 3 b) .
Discussion
This study was designed to identify the molecular abnormality in a series of HBS variants and in two reactive-site variants, 1238 Molho-Sabatier et al. and thus provide a better understanding of the structure-function relationships of ATIII and the correlation between molecular mutations and thrombosis. Analysis of these molecular defects was greatly simplified by enzymatic amplification of genomic DNA for the molecular characterization of a series of seven ATIII variants. Enzymatic amplification was followed by dot-blot analysis with ASO probes and sequencing of the reasons. First, these two amino acids are encoded by the codons CCG and CGT, both of which contain the CG dimer, which is a major site of methylation in human DNA. CG dimers might be mutation "hot spots" in the ATIII gene, as they are in the factor VIII gene (22 (23) and heparin cofactor 11 (24) , two proteins that bind either low-or high-affinity heparin. ATIII models based on the three-dimensional structure of a,-antitrypsin indicate that the positively charged amino acids Arg 47, Lys 125, Arg 129, and Lys 133 are at the surface of the molecule and may be responsible for heparin binding through ionic interactions (1, 25) . The fragment of ATIII, obtained by V8 protease digestion, which has the greatest affinity for high-affinity heparin, is 114-156; this fragment might represent part of the physiological heparin binding domain, whereas fragment 41-49 might be indirectly involved (26) . The case of the reactive-site variants is very different, because the sequence involved in this function is much more defined and these variants are always associated with a high incidence of thrombosis, whatever the mutation site (27, 28) .
ATIII reactive-site variants are totally unable to inhibit thrombin. As with other protease inhibitors, ATIII first binds to the catalytic site of the serine-protease, e.g., the Arg 393-Ser 394 bond ofthrombin. Cleavage at this site allows the stoichiometric formation of a covalent inactive complex. This reactive site of antithrombin III is structurally supported by a loop of the protein that presents this sequence to the enzyme. Cleavage of ATIII potentially induces a conformational change in the protein, which switches from a native stressed form (S) to a more relaxed form (R) (29) .
It thus is easy to understand that substitutions at the cleavage site involving PI Arg (393) (30, 32) or P'1 Ser (394) (33) preclude inactivation of thrombin and other clotting protease, because the absence of cleavage makes the formation of the ATIII-thrombin irreversible complex impossible. One of the variants of our series, ATIII Avranches, was found to bear such a mutation (393 Arg to His), identical to those found in ATIII Sheffield (30) and ATIII Glasgow (32, 33 Antiprotease activity was also abolished by mutations located in the peptide sequences adjacent to the cleavage site. The Pro 407 Leu and Ala 382 Thr mutations observed in ATIII Utah and Hamilton (34, 35) are associated with a loss of antiprotease activity. These two amino acids are extremely conserved in the serpin family; thus the nature or the location (respectively in P14 and P12) ofthe substitution may modify the presentation or the structure of the loop, so that it can no longer react with the catalytic site of thrombin (Fig. 4) 
